Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J. Sandborn WJ, et al. Among authors: ghosh s. Gastroenterology. 2020 Jun;158(8):2123-2138.e8. doi: 10.1053/j.gastro.2020.01.047. Epub 2020 Feb 8. Gastroenterology. 2020. PMID: 32044319 Free article. Clinical Trial.
Natalizumab for active Crohn's disease.
Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S; Natalizumab Pan-European Study Group. Ghosh S, et al. N Engl J Med. 2003 Jan 2;348(1):24-32. doi: 10.1056/NEJMoa020732. N Engl J Med. 2003. PMID: 12510039 Free article. Clinical Trial.
The classics in perspective.
Panés J, Ghosh S. Panés J, et al. Among authors: ghosh s. Gut. 2007 Sep;56(9):1184-6. doi: 10.1136/gut.2007.121830. Gut. 2007. PMID: 17698863 Free PMC article. No abstract available.
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.
van der Woude CJ, Stokkers P, van Bodegraven AA, Van Assche G, Hebzda Z, Paradowski L, D'Haens G, Ghosh S, Feagan B, Rutgeerts P, Dijkstra G, de Jong DJ, Oldenburg B, Farhan M, Richard T, Dean Y, Hommes DW; Initiative on Crohn's and Colitis, The Netherlands. van der Woude CJ, et al. Among authors: ghosh s. Inflamm Bowel Dis. 2010 Oct;16(10):1708-16. doi: 10.1002/ibd.21252. Inflamm Bowel Dis. 2010. PMID: 20848453 Clinical Trial.
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.
Feagan BG, Lémann M, Befrits R, Connell W, D'Haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg M, Sorrentino D, van der Woude CJ, Vermeire S, Rutgeerts P. Feagan BG, et al. Among authors: ghosh s. Inflamm Bowel Dis. 2012 Jan;18(1):152-60. doi: 10.1002/ibd.21870. Epub 2011 Oct 29. Inflamm Bowel Dis. 2012. PMID: 22038857
Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus.
Reinisch W, Van Assche G, Befrits R, Connell W, D'Haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg MS, Sorrentino D, van der Woude CJ, Vermeire S, Panes J. Reinisch W, et al. Among authors: ghosh s. J Crohns Colitis. 2012 Mar;6(2):248-58. doi: 10.1016/j.crohns.2011.11.001. Epub 2012 Jan 10. J Crohns Colitis. 2012. PMID: 22325181
13,261 results
You have reached the last available page of results. Please see the User Guide for more information.